Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience.
A joint venture between YM BioSciences (formerly York Medical) and The Center of Molecular Immunology is collaborating with Oncoscience in Europe for the development of a humanized monoclonal antibody, nimotuzumab, for the potential treatment (TheraCIM and RadioTheraCIM) and diagnosis (DiaCIM) of cancers of epithelial origin, such as breast, lung, head and neck, and pancreatic cancer. The antibody is currently undergoing phase II clinical trials.
Spicer
James
J
Guy's Hospital, Department of Medical Oncology, 3rd Floor, Thomas Guy House, St Thomas Street, London, SE1 9RT, UK. James.Spicer@gstt.nhs.uk
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011868:Radioisotopes; D051381:Rats; D012211:Rhenium
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011868:Radioisotopes; C501466:nimotuzumab; D012211:Rhenium